Peripheral Artery Disease Management

Antiplatelet Therapy

• The American College of Chest Physicians recommends single antiplatelet therapy with either aspirin 75-100 mg daily or clopidogrel 75 mg daily for cardiovascular event prevention in symptomatic PAD patients (Grade 1A recommendation) 1, 2, 3
• Single antiplatelet therapy is strongly recommended, with aspirin or clopidogrel as options, for symptomatic PAD patients (Grade 1A) 1, 3
• Avoid dual antiplatelet therapy in most PAD patients, as it does not provide additional benefit over single therapy and increases major bleeding risk (Grade 2B) 2
• Do not combine antiplatelet agents with warfarin in symptomatic PAD (Grade 1B) 1, 2

Symptom Relief and Cardiovascular Risk Reduction

• Add cilostazol 100 mg twice daily to baseline antiplatelet therapy when claudication persists despite exercise therapy and smoking cessation (Grade 2C) 1, 2
• Consider aspirin 75-100 mg daily for primary prevention of cardiovascular events in asymptomatic PAD patients ≥50 years old (Grade 2B) 1, 3
• All PAD patients should receive statin therapy, regardless of baseline cholesterol levels, with a target LDL-C <70 mg/dL for very high-risk patients 4
• Administer antihypertensive therapy to reduce MI, stroke, heart failure, and cardiovascular death risk, with a target BP <140/90 mmHg (or <130/80 mmHg if diabetes or chronic kidney disease present) 4

Post-Revascularization Management

• Continue long-term single antiplatelet therapy (aspirin 75-100 mg daily or clopidogrel 75 mg daily) after percutaneous transluminal angioplasty with or without stenting (Grade 1A) 5, 6
• Continue aspirin 75-100 mg daily or clopidogrel 75 mg daily long-term after bypass surgery (Grade 1A) 7, 5

Acute Limb Ischemia

• Immediate systemic anticoagulation with unfractionated heparin is recommended over no anticoagulation (Grade 2C) 2, 8
• Surgery is preferred over intraarterial thrombolysis for definitive management (Grade 1B) 1, 3

Peripheral Arterial Disease Management

Antiplatelet Therapy

• The American College of Cardiology recommends single antiplatelet therapy for all symptomatic PAD patients to reduce myocardial infarction, stroke, and vascular death 9
• Clopidogrel 75 mg daily is the preferred agent based on the CAPRIE trial demonstrating 24% relative risk reduction in cardiovascular events compared to aspirin in PAD patients specifically 9
• Aspirin 75-325 mg daily is an acceptable alternative if clopidogrel is contraindicated or unavailable 9
• Antiplatelet therapy is reasonable for asymptomatic patients with ABI ≤0.90 (Class IIa) 9

Antihypertensive Therapy

• ACE inhibitors or ARBs are preferred for cardiovascular protection (Class IIa for asymptomatic PAD) 9
• Beta-blockers are NOT contraindicated in PAD and are effective antihypertensives, especially if coronary artery disease coexists (Level of Evidence: A) 9

Diabetes Management

• Optimize glycemic control with target hemoglobin A1C <7% to reduce microvascular complications and potentially improve cardiovascular outcomes (Class IIa) 9
• Proper foot care is mandatory (Class I): appropriate footwear, daily inspection, skin cleansing, topical moisturizers, and urgent treatment of lesions 9

Smoking Cessation Pharmacotherapy

• All smokers with PAD must be offered pharmacological therapy (Class I, Level A) 9
• Varenicline, Bupropion, and Nicotine replacement therapy are equally effective options for smoking cessation 9

Miscellaneous

• Homocysteine-lowering therapy (folic acid, B12) is not well established even with elevated homocysteine >14 micromoles/L (Class IIb) 9
• Beta-blockers are safe and effective in PAD patients, and their use should not be avoided unnecessarily 9

Cardiovascular Protection and Symptom Management in PAD Patients

Primary Antiplatelet Therapy

• The American College of Cardiology recommends single antiplatelet therapy (either clopidogrel 75 mg daily or aspirin 75-325 mg daily) for all symptomatic PAD patients to reduce cardiovascular mortality (Grade 1A) 10
• Clopidogrel 75 mg daily is the preferred single antiplatelet agent for PAD patients based on cardiovascular outcomes, reducing cardiovascular events by 24% compared to aspirin 10

Symptom Management and Safety Considerations

• Cilostazol does not reduce cardiovascular mortality or major cardiovascular events, with no difference in rates of MI (1.0% vs 0.8%), stroke (0.5% vs 0.5%), or death (0.6% vs 0.5%) compared to placebo 11, 12, 13
• Cilostazol improves maximal walking distance by 40-60% after 12-24 weeks, with significant improvement in physical function subscales (79 more per 1,000 patients experience important benefit) 12
• The American College of Cardiology recommends against using cilostazol as the sole antiplatelet agent, as it does not reduce cardiovascular events, and patients still need clopidogrel or aspirin for mortality reduction 11

Post-Revascularization Considerations

• After lower extremity revascularization, continue long-term single antiplatelet therapy (clopidogrel 75 mg daily or aspirin 75-100 mg daily) for cardiovascular protection 10
• Dual antiplatelet therapy (aspirin plus clopidogrel) may be reasonable to reduce limb-related events post-revascularization, but evidence is limited (Grade IIb) 10

Antiplatelet Therapy and Acute Management in Peripheral Artery Disease

Core Antiplatelet Therapy for Symptomatic PAD

• All patients with symptomatic peripheral artery disease should receive a single antiplatelet agent—preferably clopidogrel 75 mg daily, or aspirin 75‑100 mg daily when clopidogrel is unsuitable—to prevent cardiovascular events. 14
• Aspirin 75‑100 mg daily is an acceptable alternative for patients who cannot take clopidogrel. 14

Antiplatelet Pitfalls (Avoidance Strategies)

• Routine dual antiplatelet therapy (aspirin + clopidogrel) for stable PAD should be avoided because it raises major‑bleeding risk without improving walking distance (Grade 2B). 14
• Combining antiplatelet agents with moderate‑intensity warfarin is not recommended unless there is a separate indication (Grade 1B). 14

Post‑Revascularization Antiplatelet Management

• After any endovascular or surgical revascularization, patients should continue long‑term single antiplatelet therapy (aspirin or clopidogrel) (Grade 1A). 14
• For below‑knee bypass using prosthetic grafts, a 12‑month course of dual antiplatelet therapy (clopidogrel + aspirin) may be considered (Grade 2C). 14

Medications Not Recommended for Claudication

• Pentoxifylline should not be prescribed for intermittent claudication because it is inferior to cilostazol and only marginally better than placebo. 14

Critical Limb Ischemia (Non‑Surgical Candidates)

• In patients with rest pain who are not surgical candidates, adding a prostanoid to baseline antiplatelet therapy can be considered, although the benefit for pain relief and ulcer healing is uncertain (Grade 2C). 14

Acute Limb Ischemia Emergency Protocol

• Immediate systemic anticoagulation with unfractionated heparin is recommended over no anticoagulation (Grade 2C). 14
• Surgical intervention is preferred to intra‑arterial thrombolysis for definitive treatment (Grade 1B). 14
• If thrombolysis is chosen, recombinant tissue‑type plasminogen activator (rt‑PA) or urokinase should be used rather than streptokinase (Grade 2C). 14

Management of Asymptomatic PAD

• For individuals with an ankle‑brachial index ≤ 0.90, low‑dose aspirin (75‑100 mg daily) may be offered for primary cardiovascular prevention (Grade 2B). 14
• Aspirin’s reduction in myocardial infarction is offset by an increase in major bleeding events over a ten‑year horizon. 14

Antithrombotic and Pharmacologic Management of Peripheral Arterial Disease

Antiplatelet Therapy (Cardiovascular Protection)

• The American College of Cardiology (ACC) recommends that all symptomatic PAD patients receive single‑agent antiplatelet therapy—either clopidogrel 75 mg daily (preferred) or aspirin 75–100 mg daily—to lower the risk of myocardial infarction, stroke, and vascular death. Grade 2A. 15
• When clopidogrel is contraindicated or unavailable, aspirin 75–100 mg daily is an acceptable alternative. [16][15]
• Routine dual antiplatelet therapy (aspirin + clopidogrel) should be avoided in stable PAD because it raises major bleeding without improving cardiovascular outcomes. Grade 2B. [17][18]
• Combining antiplatelet agents with warfarin is not recommended unless a separate indication (e.g., atrial fibrillation) exists, as it increases bleeding without added cardiovascular benefit. Grade 1B. [16][17]18

Low‑Dose Rivaroxaban + Aspirin for High‑Risk PAD

• The European Society of Cardiology (ESC) advises that symptomatic PAD patients at high ischemic risk and low bleeding risk receive rivaroxaban 2.5 mg twice daily together with aspirin 100 mg daily to reduce both major adverse cardiovascular events (MACE) and major adverse limb events (MALE). 15
• This combination is the only antithrombotic regimen proven to lower both limb‑related and cardiovascular events in PAD populations. 15
• It is specifically recommended after lower‑limb revascularization to prevent post‑procedural cardiovascular and limb complications. 15

Cilostazol for Lifestyle‑Limiting Intermittent Claudication

• The ACC recommends cilostazol 100 mg twice daily for patients with intermittent claudication who have completed at least 3 months of supervised exercise therapy and smoking cessation, when claudication remains lifestyle‑limiting. [16][17]
• Cilostazol increases maximal walking distance by 40–60 % and yields a meaningful functional benefit in approximately 79 additional patients per 1,000 treated. Level A evidence. 18
• Absolute contraindication: any degree of heart failure; therapy must be stopped immediately if heart failure develops because of increased mortality risk with phosphodiesterase‑III inhibition. [16][17]

Therapies Not Recommended in PAD

• Pentoxifylline should not be used for intermittent claudication; it offers only marginal benefit over placebo and is inferior to cilostazol. Level C evidence. [16][17]
• Chelation therapy (e.g., EDTA) is not indicated and may cause harmful adverse effects. [16][17]
• L‑arginine, propionyl‑L‑carnitine, and ginkgo biloba have either marginal or unestablished efficacy for claudication and are not recommended. [16][17]

Supervised Exercise Therapy (Adjunct to Pharmacotherapy)

• The ACC and ESC endorse supervised exercise training (SET) as first‑line therapy for symptomatic PAD, performed for 30–45 minutes per session, at least three times per week, for a minimum of 12 weeks. Level A evidence. [16][17]15
• High‑intensity walking (targeting 77–95 % of maximal heart rate or a Borg rating of 14–17) should be employed to maximize improvements in walking performance. 15
• SET remains recommended as an adjunctive therapy even after endovascular revascularization to sustain functional gains. 15

Antiplatelet Management in Peripheral Artery Disease Patients with Coronary Stents

Core Antiplatelet Strategy

Concomitant Medical Therapy

Post‑Revascularization Management

Avoidance of Harmful Therapies

Safety Considerations